ArticleKidney international reports2022
Efficacy of Immunomodulatory Drugs in Combination With Dexamethasone in Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Monoclonal and monotypic immunoglobulin-related kidney diseases in young people: literature review including evolving entities.Pediatric nephrology (Berlin, Germany) · 2026Review
- Recurrent IgA1-λ-Type PGNMID Achieving Remission with Conventional Immunosuppressive Therapy.Internal medicine (Tokyo, Japan) · 2026Article
- Proliferative Glomerulonephritis With Monoclonal Ig Deposits Without Detectable Clones: Navigating Empirical Clone-Directed Therapy.Kidney international reports · 2025Article
- Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report.Kidney medicine · 2025Article
- Proliferative glomerulonephritis with monoclonal immunoglobulin deposition coexisting with ANCA-associated glomerulonephritis: a case report.Frontiers in immunology · 2025Article
- Concurrent presentation of proliferative glomerulonephritis with monoclonal immunoglobulin deposits and light chain proximal tubulopathy: a case report and review of the literature.Frontiers in medicine · 2025Article
- Hemato-Renal Profile of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits.Indian journal of nephrology · 2024Article
- Case report: A case of proliferative glomerulonephritis with monoclonal kappa-light chain deposits treated with daratumumab combination therapy.Frontiers in medicine · 2024Article
- IgM kappa proliferative glomerulonephritis with monoclonal immunoglobulin deposition complicated with nocardiosis dermatitis: a case report and review of literature.Frontiers in medicine · 2024Article
- Unraveling monoclonal gammopathy of renal significance: a mini review on kidney complications and clinical insights.Frontiers in nephrology · 2024Review
- Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones.Kidney international reports · 2023Article
- The Uncertainty Puzzle of Monoclonal Gammopathy of Renal Significance Without Detectable Clones.Kidney international reports · 2023Article
- Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: An Immunologic Crossroads.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immunomodulatory drugs (IMiDs) plus dexamethasone are effective for plasma cell dyscrasias, but the treatment efficacy of IMiD in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) has been rarely reported. Methods: We retrospectively analyzed the clinicopathologic data of 64 patients with PGNMID (steroid, IMiD, and bortezomib and dexamethasone/Rituximab [BD/RTX] groups) from January 1, 2010 to December 31, 2020, at the National Clinical Research Center of Kidney Disease in Nanjing. The prognosis of patients receiving different treatment regimens were compared. Factors potentially affecting renal prognosis and renal response were evaluated. Results: Twenty-eight, 26 and 10 PGNMID patients were divided into IMiD group, steroid group and BD/RTX group respectively. The rate of serum M protein detection was significantly lower in the steroid group than in the other 2 groups. Renal remission ( Conclusion: Our results suggest that IMiDs plus dexamethasone is effective for achieving renal remission in PGNMID patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.